Rebecca Bungay
Education
M.S., public health, McGill University; B.S., psychology, Memorial University Newfoundland
Summary of Experience
Ms. Bungay specializes in epidemiology and health economics and outcomes research, with a focus on real-world evidence generation. She has worked with a range of data sources and methodologies, including health insurance claims databases, patient and health care provider surveys, medical chart reviews, and hybrid time and motion studies. Her research includes retrospective assessments of disease incidence and prevalence, treatment patterns, survival outcomes, risk factors, burden of illness, and patient-reported outcomes. She has conducted studies across multiple therapeutic areas, including oncology, hematology, psychiatry, and hepatology. Ms. Bungay’s research has been published in peer-reviewed journals and presented at various clinical and health economics conferences.
-
Agitation in individuals with Alzheimer's disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience
Dementia, 2025
2025Grossberg G, Willey C, Houle C, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guerin A, Ismail Z, Aggarwal J
-
Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
Advances in Therapy, 2024
2024Lacy B, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre A
-
Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States
Current Medical Research and Opinion, 2024
2024Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, Guerin A, Fan T
-
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder
Journal of Managed Care & Specialty Pharmacy, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Childress A
-
Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder: a claims-based case-cohort study
Child and Adolescent Psychiatry and Mental Health, 2024
2024Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, Guerin A, Childress A
-
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder
Journal of Medical Economics, 2024
2024Schein J, Cloutier M, Bungay R, Gauthier-Loiselle M, Childress A
-
A real-world assessment of healthcare costs associated with agitation in Alzheimer’s dementia
Journal of Medical Economics, 2024
2024Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, Guerin A, Aggarwal J
-
Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study
BMC Psychiatry, 2023
2023Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Arpin E, Guerin A, Childress A
-
Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States
BMC Infectious Diseases, 2023
2023Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Gauthier-Loiselle M, Bungay R, Cloutier M, Sarnecki M, Saade E
-
Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs
Journal of Medical Economics, 2023
2023Jesudian AB, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Chen J, Guérin A, Bumpass B, Borroto D, Joseph G, Dashputre AA
-
Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States
Journal of Managed Care & Specialty Pharmacy, 2023
2023Hernandez-Pastor L, Geurtsen J, Baugh B, El Khoury AC, Kalu N, Krishnarajah G, Gauthier-Loiselle M, Bungay R, Cloutier M, Saade E
-
Real-World Experience of Pediatric Patients Treated with Peanut (Arachis Hypogaea) Allergen Powder-Dnfp
Annals of Allergy, Asthma & Immunology, 2023
2023Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, McCann W
-
Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD
Current Medical Research and Opinion, 2022
2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A
-
Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study
Advances in Therapy, 2022
2022Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Guerin A, Childress A
-
Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
Kidney Medicine, 2022
2022Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, Guérin A, Farag YMK, Wish JB
-
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study
Current Medical Research and Opinion, 2021
2021Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, Guérin A, Lefebvre P
-
Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors
Journal of Medical Economics, 2021
2021 -
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective
Journal of Managed Care & Specialty Pharmacy, 2021
2021Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, Guérin A
-
May 8, 2023
-
December 3, 2025
-
March 10, 2025
-
June 4, 2024
-
October 23, 2023